Rhythm Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Rhythm Pharmaceuticals sono diminuiti a un tasso medio annuo di -18.2%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 77.3%.

Informazioni chiave

-18.2%

Tasso di crescita degli utili

-6.7%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	77.3%
Rendimento del capitale proprio	-169.6%
Margine netto	-232.4%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

Ripartizione dei ricavi e delle spese

Come Rhythm Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:RYTM Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	113	-262	139	227
30 Jun 24	102	-261	134	222
31 Mar 24	92	-274	127	226
31 Dec 23	77	-185	118	135
30 Sep 23	62	-186	111	129
30 Jun 23	44	-182	103	116
31 Mar 23	34	-181	95	114
31 Dec 22	24	-181	92	109
30 Sep 22	17	-181	87	117
30 Jun 22	13	-176	82	123
31 Mar 22	5	-166	75	117
31 Dec 21	3	-70	68	104
30 Sep 21	1	-62	61	95
30 Jun 21	0	-60	54	90
31 Mar 21	0	-56	48	88
31 Dec 20	0	-134	46	90
30 Sep 20	0	-132	42	93
30 Jun 20	0	-134	42	97
31 Mar 20	0	-146	42	109
31 Dec 19	0	-141	37	109
30 Sep 19	0	-133	36	103
30 Jun 19	0	-115	34	88
31 Mar 19	0	-87	31	61
31 Dec 18	0	-74	28	50
30 Sep 18	0	-59	24	38
30 Jun 18	0	-53	18	33
31 Mar 18	0	-47	13	30
31 Dec 17	0	-38	10	23
30 Sep 17	0	-36	8	22
30 Jun 17	0	-32	7	21
31 Mar 17	0	-30	6	21
31 Dec 16	0	-29	6	20
30 Sep 16	0	-27	6	18
30 Jun 16	0	-23	6	14
31 Mar 16	0	-17	5	10
31 Dec 15	0	-12	3	7
30 Sep 15	0	-6	2	4
30 Jun 15	0	-3	1	2
31 Mar 15	0	-5	1	4
31 Dec 14	0	-6	1	5

Guadagni di qualità: RYTM al momento non è redditizia.

Margine di profitto in crescita: RYTM al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: RYTM non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 18.2% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di RYTM nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: RYTM non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: RYTM ha un Return on Equity negativo ( -169.58% ), in quanto al momento non è redditizio.

Rhythm Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

New minor risk - Profitability

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Executive VP & Head of North America notifies of intention to sell stock

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Consensus EPS estimates fall by 14%, revenue upgraded

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Consensus EPS estimates fall by 61%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Rhythm Pharmaceuticals: Action Too Specific

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Chief Technical Officer notifies of intention to sell stock

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Price target increased by 9.0% to US$53.78

Price target increased by 10% to US$52.67

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Forecast to breakeven in 2026

Chief Technical Officer notifies of intention to sell stock

Price target increased by 7.8% to US$47.67

CFO & Treasurer exercised options and sold US$860k worth of stock

Price target increased by 8.4% to US$44.22

CFO & Treasurer notifies of intention to sell stock

Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Executive VP & Head of North America exercised options and sold US$180k worth of stock

Executive VP & Head of North America notifies of intention to sell stock

Consensus revenue estimates increase by 28%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 19%

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

Consensus EPS estimates fall by 10%

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Price target increased by 8.6% to US$36.56

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome